Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. More Details
+ 2 more risks
Flawless balance sheet and overvalued.
Share Price & News
How has Destiny Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DEST is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: DEST's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
7 Day Return
1 Year Return
Return vs Industry: DEST exceeded the UK Biotechs industry which returned 38.4% over the past year.
Return vs Market: DEST exceeded the UK Market which returned 19% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Destiny Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StHave Insiders Sold Destiny Pharma plc (LON:DEST) Shares Recently?
1 week ago | Simply Wall StCould The Destiny Pharma plc (LON:DEST) Ownership Structure Tell Us Something Useful?
2 months ago | Simply Wall StIs Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Is Destiny Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DEST is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: DEST is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DEST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DEST is good value based on its PB Ratio (6.1x) compared to the GB Biotechs industry average (6.6x).
How is Destiny Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if DEST's forecast earnings growth is above the savings rate (0.9%).
Earnings vs Market: Insufficient data to determine if DEST's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if DEST's revenue is forecast to grow faster than the UK market.
High Growth Revenue: DEST is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DEST's Return on Equity is forecast to be high in 3 years time
How has Destiny Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DEST is currently unprofitable.
Growing Profit Margin: DEST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DEST is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.
Accelerating Growth: Unable to compare DEST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DEST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: DEST has a negative Return on Equity (-43.51%), as it is currently unprofitable.
How is Destiny Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: DEST's short term assets (£11.4M) exceed its short term liabilities (£1.3M).
Long Term Liabilities: DEST has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DEST is debt free.
Reducing Debt: DEST has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DEST has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DEST has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 29.8% each year.
What is Destiny Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DEST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DEST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DEST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DEST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DEST's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Neil Clark (57 yo)
Mr. Neil Robert Clark, BSc, FCA, has been the Chief Executive Officer and Executive Director at Destiny Pharma plc since April 13, 2017 and January 20, 2017 respectively. Mr. Clark has been Consultant of P...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD452.87K) is above average for companies of similar size in the UK market ($USD329.30K).
Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.
Experienced Management: DEST's management team is considered experienced (2.8 years average tenure).
Experienced Board: DEST's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DEST insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.5%.
Destiny Pharma plc's company bio, employee growth, exchange listings and data sources
- Name: Destiny Pharma plc
- Ticker: DEST
- Exchange: AIM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£76.174m
- Shares outstanding: 59.86m
- Website: https://www.destinypharma.com
Number of Employees
- Destiny Pharma plc
- Sussex Innovation Centre
- Unit 36
- East Sussex
- BN1 9SB
- United Kingdom
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involve...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/17 21:55|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.